Trial Profile
A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 479 in Adult Japanese Patients with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2016
Price :
$35
*
At a glance
- Drugs Ganitumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 26 May 2016 New trial record